Our Strength
Our core strength is corneal endothelial cell analysis (corneal reading) at Specular Solutions. Typically, the FDA requires pharmaceutical companies, if they have a device, drug, or solution that may adversely affect the corneal endothelium, to add corneal endothelial specular microscopy morphometric data to their list of needed assessments. That is where we come in. After the clinical sites take the clinical specular photomicrographs, they send these to us (usually via secure email). Our over 30 years of experience in the field doing this kind of analysis sets us apart. Working for most of that time with one of the foremost corneal researchers in the world, Henry F. Edelhauser, Ph.D., has enabled us to foster this expertise.
Our Vision
We strive to help both large and small ophthalmic pharmaceutical companies to get the most accurate, reliable, and reproducible, over time, corneal endothelial specular microscopy analysis data (corneal reading) that is possible with on-time delivery. This will help our clients to navigate (at least in terms of corneal endothelial change over time) the specular microscopy data with the FDA.